Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBT440 in healthy subjects under hypoxic conditions
NCT03051711Phase 1Terminated
- Sponsor
- Global Blood Therapeutics
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of voxelotor in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Global Blood Therapeutics. Primary endpoint: Change in oxygen saturation at rest and exercise under hypoxic conditions at Day 15. Started Dec 2016; status: terminated.
02
Drugs
voxelotor
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03051711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051711.